PLYMOUTH, Minn., Sept. 24, 2015 (GLOBE NEWSWIRE) -- Entellus Medical, Inc. ("Entellus Medical" or the "Company") (NASDAQ:ENTL), a medical technology company focused on the design, development and commercialization of products for the minimally invasive treatment of chronic and recurrent sinusitis patients in the physician office setting or operating room, today announced the release of its MiniFESS family of products and its FocESS Sinuscopes, representing a total of eleven new products. These products are designed to enable, enhance and expand the number of patients who can benefit from the superior patient experience and improved healthcare economics offered by office-based treatment.
In combination with effective local anesthesia protocols, the MiniFESS family of products features eight steel surgical instruments designed to enable procedures from turbinate reductions to anterior ethmoidectomies to be performed in the ENT physician office instead of the operating room. This transition to the ENT physician office offers patients reduced risk and requires less time than a traditional operating room procedure using general anesthesia.
The FocESS Sinuscope line features three scopes with 0-, 30-, and 45-degree viewing angles. At 3 millimeters in diameter and 150 millimeters in length, and with a field of view that is as much as 30 millimeters greater than competing devices, the FocESS Sinuscopes are designed to make office procedures even easier for ENT physicians.
"We are committed to bringing technologies to the ENT market that offer the opportunity to transform the patient and physician experience," said Robert White, President and CEO of Entellus Medical. "We believe that the MiniFESS and FocESS product lines, along with our recently announced exclusive distribution of Fiagon Image Guidance Technology, will continue to enable, enhance and expand the number of patients that ENT physicians can treat in the office using our technologies."
About Chronic Sinusitis and Balloon Sinus Dilation:
Chronic sinusitis affects approximately 29 million American adults, making it one of the most common health problems in the United States. It is more prevalent than heart disease and asthma, and has a negative impact on quality of life with chronic symptoms and effects including facial pain and pressure, headaches, fatigue, loss of smell, and sinus infections.
About Entellus Medical, Inc.
Entellus Medical is a medical technology company focused on the design, development and commercialization of products for the minimally invasive treatment of chronic and recurrent sinusitis patients in the physician office setting or operating room. Its XprESS family of products is used by ENT physicians to open narrowed or obstructed sinus drainage pathways using balloon sinus dilation. When used as a stand-alone therapy, Entellus Medical's balloon sinus dilation products are the only devices proven in a sufficiently powered prospective, multicenter, randomized, controlled trial to be as effective as functional endoscopic sinus surgery ("FESS"). Patients treated with Entellus Medical's products in this trial in the ENT physician's office also experienced faster recovery, less bleeding at discharge, less use of prescription pain medication and fewer post-procedure debridements than patients receiving FESS. In addition to its XprESS line of products, Entellus Medical has recently introduced additional products designed to aid in the diagnosis, treatment and post-operative care of patients suffering from chronic sinusitis.
Entellus Medical currently markets its products in the United States, Europe and Canada and sells its products through a direct sales force in the United States and the United Kingdom. For more information, please visit the Company's website at www.entellusmedical.com.
Forward-Looking Statements:
All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are based on the current expectations of Entellus Medical's management and involve known and unknown risks and uncertainties that may cause Entellus Medical's actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Such risks and uncertainties include, among others, adoption by ENT physicians of the Company's MiniFESS family of products and FocESS Sinuscopes, the benefits the Company expects to achieve as a result of the collaboration with Fiagon and the integration of the Company's product portfolio and the Fiagon IGS. Other factors that could cause actual results to differ materially from those contemplated in this press release can be found under the caption "Risk Factors" in the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2014 filed with the Securities and Exchange Commission ("SEC"), and in its other reports filed with the SEC. Entellus Medical undertakes no obligation to update or revise any forward-looking statements, even if subsequent events cause its views to change.